- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05613738
177Lu-PSMA-EB-01 in Patients With Metastatic Castration-resistant Prostate Cancer
November 6, 2022 updated by: Peking Union Medical College Hospital
Safety and Dosimetry of 177Lu-PSMA-EB-01 in Patients With Metastatic Castration-resistant Prostate Cancer
This is a pilot study to assess the safety and measure image-based absorbed dose of 177Lu-PSMA-EB-01, a new PSMA-specific radiopharmaceutical, in patients with metastatic castration resistant prostate cancer (mCRPC) who will undergo radioligand therapy (RLT).
All patients underwent 68Ga-PSMA and 18F-FDG PET/CT for selection and were randomly divided into three groups of 3 people each.The three groups received an approximately 1.11 GBq (30mCi), 1.85 GBq (50 mCi) and 2.59 GBq (70mCi) of 177Lu-PSMA-EB-01 up to 2 cycles, respectively.
Study Overview
Status
Recruiting
Detailed Description
Prostate cancer is the most frequent malignant tumor in men worldwide.
Prostate-specific membrane antigen (PSMA), is a surface molecule specifically expressed by prostate tumors which was shown to be a valid target for radiotherapy.
177Lu-PSMA-617, a urea-based compound, provide an effective target for the treatment of metastatic castration-resistant prostate cancer.
However, a major problem in the therapeutic use of 177Lu-PSMA-617 has been its short half-life and fast rate of clearance.
The investigators designed and synthesized a new radiopharmaceutical, named 177Lu-PSMA-EB-01.
EB(Evans Blue)can bind to albumin to slow down its plasma clearance rate, thereby increasing tumor accumulation and reducing the total dosage of Lu-177.
Hence, EB-PSMA-01 may be an option for consideration due to limited supply of Lu-177, by which more patients may be benefited by this version of 177Lu-EB-PSMA-01.
This study was designed to investigate the safety, dosimetry and preliminary effects of 177Lu-EB-PSMA-01 in patients with metastatic castration resistant prostate cancer.
Study Type
Interventional
Enrollment (Anticipated)
9
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100730
- Recruiting
- Peking Union Medical College Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- progressive metastatic castration-resistant prostate cancer
- tumors with high PSMA expression confirmed on 68Ga-PSMA PET/CT
Exclusion Criteria:
- a serum creatinine level of more than 150 μmol per liter
- a hemoglobin level of less than 10.0 g/dl
- a white-cell count of less than 4.0× 109/L
- a platelet count of less than 100 × 109/L
- a total bilirubin level of more than 3 times the upper limit of the normal range
- a serum albumin level of more than 3.0 g per deciliter
- cardiac insufficiency
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1.11 GBq (30 mCi) of 177Lu-PSMA-EB-01
All patients were intravenous injected with single dose 1.11 GBq (30 mCi) of 177Lu-PSMA-EB-01 then monitored at 3 hours, 24 hours, 48 hours, 72 hours, and 168 hours post-injection.
|
All patients were intravenous injected with single dose 1.11 GBq (30 mCi) of 177Lu-PSMA-EB-01 then monitored at 3 hours, 24 hours, 48 hours, 72 hours, and 168 hours post-injection.
|
Experimental: 1.85 GBq (50 mCi) of 177Lu-PSMA-EB-01
All patients were intravenous injected with single dose 1.85 GBq (50 mCi) of 177Lu-PSMA-EB-01 then monitored at 3 hours, 24 hours, 48 hours, 72 hours, and 168 hours post-injection.
|
All patients were intravenous injected with single dose 1.85 GBq (50 mCi) of 177Lu-PSMA-EB-01 then monitored at 3 hours, 24 hours, 48 hours, 72 hours, and 168 hours post-injection.
|
Experimental: 2.59 GBq (70 mCi) of 177Lu-PSMA-EB-01
All patients were intravenous injected with single dose 2.59 GBq (70 mCi) of 177Lu-PSMA-EB-01 then monitored at 3 hours, 24 hours, 48 hours, 72 hours, and 168 hours post-injection.
|
All patients were intravenous injected with single dose 2.59 GBq (70 mCi) of 177Lu-PSMA-EB-01 then monitored at 3 hours, 24 hours, 48 hours, 72 hours, and 168 hours post-injection.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dosimetry of normal organs and tumors
Time Frame: through study completion, an average of 4 weeks
|
The semiquantitative dosimetry will be performed based on SPECT/CT acquisitions after the first administration of 177Lu-PSMA-EB-01.
The dose delivered to normal organs and tumors will be recorded.
|
through study completion, an average of 4 weeks
|
Hematologic adverse events collection
Time Frame: through study completion, an average of 6 months
|
Hematologic status were performed before and every 2 weeks after administration of radiopharmaceutical.
Adverse events were categorized using the Common Toxicity Criteria for Adverse Events 5.0
|
through study completion, an average of 6 months
|
Hepatic and renal toxic events collection
Time Frame: through study completion, an average of 6 months
|
Liver function, and renal function were performed before and 4 weeks after administration of radiopharmaceutical.
Adverse events were categorized using the Common Toxicity Criteria for Adverse Events 5.0.
|
through study completion, an average of 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PSA Response
Time Frame: through study completion, an average of 6 months
|
The serum PSA response was documented semimonthly until 6 weeks after the administration of 177Lu-PSMA-EB-01.
PSA response was classified as the following: partial response (PR) if PSA decrease ≥50%, progressive disease (PD) if PSA increase ≥ 25% and stable disease (SD) if PSA increase <25% or PSA decrease <50%.
|
through study completion, an average of 6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Zhaohui Zhu Zhu, MD, Peking Union Medical College Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
November 23, 2022
Primary Completion (Anticipated)
June 30, 2023
Study Completion (Anticipated)
November 15, 2023
Study Registration Dates
First Submitted
October 25, 2022
First Submitted That Met QC Criteria
November 6, 2022
First Posted (Actual)
November 14, 2022
Study Record Updates
Last Update Posted (Actual)
November 14, 2022
Last Update Submitted That Met QC Criteria
November 6, 2022
Last Verified
October 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PUMCH-NM-PSMAEB01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Castration-resistant Prostate Cancer
-
Myovant Sciences GmbHRecruitingMetastatic Castration-Resistant Prostate Cancer | Metastatic Castration-Sensitive Prostate Cancer | Non-Metastatic Castration-Resistant Prostate CancerUnited States
-
Janux TherapeuticsRecruitingProstate Cancer | Metastatic Castration-resistant Prostate Cancer | Castration Resistant Prostatic CancerUnited States, Australia
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Clarus TherapeuticsRecruitingProstate Cancer | Castration-resistant Prostate Cancer | Metastatic Castration-resistant Prostate CancerUnited States
-
Universität des SaarlandesRecruitingProstate Cancer Metastatic | Advanced Prostate Carcinoma | Castration Resistant Prostatic CancerGermany
-
Vadim S KoshkinEli Lilly and Company; Prostate Cancer FoundationActive, not recruitingCastration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Castration-resistant Prostate Cancer | Metastatic Prostate Adenocarcinoma | Metastatic Castration-resistant Prostate CarcinomaUnited States
-
Massachusetts General HospitalBayerCompletedProstate Cancer | Castration-resistant Prostate Cancer | Castration-resistant Prostate Cancer Metastatic to BoneUnited States
-
Rohan GarjeJanssen Scientific Affairs, LLCNot yet recruitingCastration-resistant Prostate Cancer | Metastatic Prostate Cancer | Metastatic Castration-resistant Prostate CancerUnited States
-
BAMF HealthRecruitingMetastatic Castration-resistant Prostate CancerUnited States
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingMetastatic Castration-resistant Prostate CancerChina
-
Hinova Pharmaceuticals Inc.CompletedMetastatic Castration Resistant Prostate CancerChina
Clinical Trials on 1.11 GBq (30 mCi) of 177Lu-PSMA-EB-01
-
Peking Union Medical College HospitalCompletedMetastatic Castration-resistant Prostate CancerChina
-
Peking Union Medical College HospitalNational Institute for Biomedical Imaging and Bioengineering (NIBIB)RecruitingMetastatic Castration-resistant Prostate CancerChina
-
Peking Union Medical College HospitalRecruiting
-
Peking Union Medical College HospitalRecruiting
-
Peking Union Medical College HospitalRecruitingDiagnosis of Renal Cell Carcinoma on 68Ga-PSMA PET-CT and Radioligand Therapy With 177Lu-EB-PSMA-617Renal Cell CarcinomaChina
-
Peking Union Medical College HospitalRecruitingAdenoid Cystic CarcinomaChina
-
Peking Union Medical College HospitalRecruitingNeuroendocrine TumorsChina
-
Peking Union Medical College HospitalNational Institute for Biomedical Imaging and Bioengineering (NIBIB)UnknownMetastatic Castration-resistant Prostate CancerChina